版本:
中国

BRIEF-Allergan reports topline Phase II data supporting advancement of Botox for the treatment of major depressive disorder

April 5 Allergan Plc

* Allergan reports topline Phase II data supporting advancement of Botox® (onabotulinumtoxina) for the treatment of major depressive disorder (MDD)

* Allergan Plc - Botox 30 U dose demonstrated numerically superior efficacy in madrs total score compared to placebo

* Allergan Plc - Both secondary efficacy variables (CGI-S and HAMD-17) showed numerically superior efficacy over placebo in Phase II study

* Allergan Plc - 50 units of Botox did not demonstrate superior efficacy over placebo in Phase II study

* Allergan Plc - Both 30 units and 50 units of Botox were well tolerated in Phase II study

* Allergan - Plan to move forward and develop a Phase 3 program for a potential new treatment option for patients adults with major depressive disorder Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐